Skip to main content
Immuno Oncology

Syngeneic Mouse Models

Since 1998, ingenious targeting laboratory has supported immuno oncology research with custom mouse models that enable syngeneic tumor studies, providing immunocompetent platforms for evaluating cancer immunotherapies, checkpoint inhibitors, and combination treatment strategies.

Syngeneic tumor models involve implanting tumor cell lines into genetically compatible mouse hosts, enabling study of tumor immunity in the context of a fully functional immune system.

2,500+
Projects Completed
800+
Publications
26+
Years Experience
100%
Success Rate

Key Advantages of Syngeneic Models

Intact Immune System

Unlike xenograft models, syngeneic models have functional T cells, B cells, NK cells, and myeloid populations.

Tumor Microenvironment

Immune infiltration and tumor immune interactions can be studied in physiological context.

Immunotherapy Testing

Essential for checkpoint inhibitors and other immunotherapies that require functional immunity.

Rapid Tumor Growth

Established cell lines produce consistent, reproducible tumors for study.

Common Syngeneic Tumor Lines

C57BL/6 Compatible Lines

LineTypeCharacteristics
MC38Colon carcinomaWidely used for checkpoint studies. Moderate immunogenicity. Good response to anti PD1/PDL1.
B16 F10MelanomaPoorly immunogenic. Used for aggressive tumor studies.
LLCLewis Lung CarcinomaLung adenocarcinoma model. Moderate immunogenicity.
E0771Breast CancerMammary carcinoma model for breast cancer studies.
Panc02Pancreatic CancerPancreatic adenocarcinoma model.

BALB/c Compatible Lines

LineTypeCharacteristics
CT26Colon carcinomaHighly used for immunotherapy studies. Good response to checkpoint blockade.
4T1Breast CancerAggressive mammary carcinoma. Spontaneous metastasis to lung.
RencaRenal CarcinomaKidney cancer model.
A20LymphomaB cell lymphoma model.

Humanized Checkpoint Models for Syngeneic Studies

PD1 Humanized

Testing anti human PD1 antibodies (pembrolizumab, nivolumab)

PDL1 Humanized

Testing anti PDL1 antibodies (atezolizumab, durvalumab)

CTLA4 Humanized

Testing anti CTLA4 antibodies (ipilimumab)

Dual PD1/CTLA4

Combination checkpoint blockade studies

What Researchers Say

iTL produced a new conditional mouse model for us and the quality of service was exceptional. The team is extremely knowledgeable and the work was completed at the highest possible standards. My project manager was excellent and always happy to answer technical questions and keep me up to date with progress and potential problems. I would recommend iTL highly and will use them again in the future if I need to generate a new mouse line.

Albert Basson, PhD

King's College London

✦ New for 2026

Breeding Scheme Architect

Plan complex multi-allele breeding strategies, calculate expected genotype ratios, and estimate time to experimental cohorts—all before starting your project.

Visualize multi-generation breeding paths
Calculate Mendelian ratios automatically
Estimate timeline to study-ready cohorts

Free Research Tool

No account required

Allele 1Gene-flox (conditional)
Allele 2Cre-driver (tissue-specific)
TargetHomozygous knockout

→ 3 generations to target genotype

Start Your Syngeneic Tumor Study

Our scientific consultants can help you select the optimal syngeneic models and humanized checkpoint combinations for your immuno oncology program.

Frequently asked questions

Syngeneic models have intact immune systems (functional T cells, B cells, NK cells, myeloid populations), enabling study of tumor immune interactions and immunotherapy testing. Xenograft models use immunodeficient hosts, preventing evaluation of immune mediated therapeutic responses.

Common C57BL/6 compatible lines include MC38 (colon carcinoma, responsive to checkpoint blockade), B16 (melanoma, poorly immunogenic), LLC (lung carcinoma), E0771 (breast cancer), and Panc02 (pancreatic cancer). Selection depends on tumor type and immunogenicity requirements.

Yes. Humanized checkpoint models (PD1, PDL1, CTLA4, LAG3, TIM3) can be combined with syngeneic tumor cell lines to create systems where both tumor and immune compartments express human targets, enabling evaluation of checkpoint blockade in immunocompetent animals.

Syngeneic tumor responses are validated through tumor growth measurement, survival analysis, immune cell infiltration (flow cytometry, immunohistochemistry), cytokine profiling, and functional assessment of immune cell activation.

Lab Signals

Track Your Syngeneic Tumor Study

Stay informed on your immuno-oncology model development, tumor cell line compatibility, and checkpoint inhibitor testing progress.

Subscribe Free

Related Humanized Models